Trial 10M-17-3


PHII-143 A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Immunotherapy
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Gino In, M.D.
Other Trial Staff:  Ramona Lujan, Coordinator, Lusine Raddatz, D.M., Victoria Amran, D.M., Gina Tse, Coordinator, Shamim Jhimlee, Coordinator, Laurie De Oliveira, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.